Bispecific T-Cell Engager

Mechanism

Related News

Cancer monoclonal antibodies market seen reaching USD 135.2 billion by 2033

Apr 20, 2026

The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.

First Patient Achieves Remission With Subcutaneous Blinatumomab in Ultra-Rare MPAL

Feb 20, 2026

A Phase II trial led by WVU Cancer Institute reports the first-ever use of subcutaneous blinatumomab in CD19-positive mixed phenotype acute leukemia, with the first patient achieving complete remission after one cycle.